QTORIN rapamycin 3.9 percent gel

Name: QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Dosage forms and strengths
Published: 2026-09-14T15:39:06-04:00

Microcystic lymphatic malformations

Manufacturer: Palvella Therapeutics
Regulatory submission: NDA submitted August 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Dosage forms and strengths

2 evidence topics · 2 sources

Topical formulation and strength

“QTORIN™ rapamycin 3.9% topical gel” (opens the source at this quote in a new tab)

Formulation stability

“Enhanced chemical stability of rapamycin at room temperature for 36 months.” (opens the source at this quote in a new tab)

Material safety data sheet

No evidence found.